{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"34.5","value":"2.8"},{"groupId":"OG001","lowerLimit":"1.2","upperLimit":"65.2","value":"2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"264"},{"groupId":"OG001","value":"142"}],"units":"Participants"}],"description":"TTR was defined as the time from randomization to the first documentation of objective tumor response according to RECIST v1.1 as assessed by investigator (CR or PR) which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.","dispersionType":"Full Range","groups":[{"description":"Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.","id":"OG000","title":"Avelumab + Axitinib"},{"description":"Participants with aRCC received sunitinib 50 mg orally, QD on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2 in 6-week cycles). Each treatment cycle was of 42 days.","id":"OG001","title":"Sunitinib"}],"paramType":"MEDIAN","populationDescription":"FAS included all randomized participants. Here \"Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 89 months)","title":"TTR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression","type":"SECONDARY","unitOfMeasure":"Months"}